Clinical Sub-Groups of Multiple Sclerosis in Relation to HLA: DR Alleles as Possible Markers of Disease Progression
- 1 May 1985
- journal article
- research article
- Published by Cambridge University Press (CUP) in Canadian Journal of Neurological Sciences
- Vol. 12 (2) , 106-110
- https://doi.org/10.1017/s0317167100046795
Abstract
We have examined the distribution of HLA antigens in 70 multiple sclerosis (MS) patients divided in three groups defined according to clinical criteria: benign MS, severe MS, cerebellar MS. We have found a significant association between severe MS and HLA-DR2, and between benign MS of more than 15 years of evolution and HLA-DR3. We review previous work along the same line and conclude that the association of HLA antigens with “clinical subgroups of MS” could indicate a genetically based heterogeneity of the disease and offer help in establishing a prognosis.This publication has 13 references indexed in Scilit:
- HLA and heterogeneity of multiple sclerosisNeurology, 1982
- HLA-TYPING IN MULTIPLE SCLEROSIS SIBLING PAIRSThe Lancet, 1982
- HLA profiles in multiple sclerosis suggest two forms of disease and the existence of protective haplotypesJournal of the Neurological Sciences, 1982
- Cerebro spinal fluid C2 and HLA system in multiple sclerosisTissue Antigens, 1982
- Genetic basis of multiple sclerosis: HLA antigens, disease progression, and oligoclonal IgG in CSFActa Neurologica Scandinavica, 1979
- Microdroplet Testing for HLA-A, -B, -C, and -D Antigens: The Philip Levine Award LectureAmerican Journal of Clinical Pathology, 1978
- Criteria for the clinical diagnosis of multiple sclerosisNeurology, 1976
- HISTOCOMPATIBILITY DETERMINANTS IN MULTIPLE SCLEROSIS, WITH SPECIAL REFERENCE TO CLINICAL COURSEThe Lancet, 1973
- Microdroplet Assay of Human Serum CytotoxinsNature, 1964